Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

February 28, 2027

Conditions

COVID-19ARDSAcute Respiratory Distress Syndrome

Interventions

BIOLOGICAL

Human umbilical cord mesenchymal stem cells + best supportive care

hUC-MSC product will be administered intravenously in addition to the standard of care treatment.

OTHER

Placebo control + best supportive care

Placebo control will be administered intravenously in addition to the standard of care treatment.

All Listed Sponsors

lead

Baylx Inc.

INDUSTRY

NCT04452097 - Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS | Biotech Hunter | Biotech Hunter